Personal HistoryJulie Kreyenbuhl, Pharm.D., Ph.D., is a Research Investigator and Assistant Director of the Research Core for the VA VISN 5 Mental Illness Research, Education, and Clinical Center (MIRECC) and an Associate Professor of Psychiatry in the Division of Services Research, Department of Psychiatry, University of Maryland School of Medicine. Dr. Kreyenbuhl received a Pharm.D. from Mercer University College of Pharmacy and Health Sciences in 1993 and a Ph.D. in Pharmaceutical Health Services Research from the University of Maryland School of Pharmacy in 1999. She completed a post-doctoral fellowship at the Maryland Psychiatric Research Center in 2000.
Dr. Kreyenbuhl's primary research focus is the pharmacoepidemiology of serious mental illness, primarily schizophrenia. She was the recipient of a K01 Research Career Award from NIMH that focused on prescription decision-making and patterns of use of complex, multidrug regimens in schizophrenia. Dr. Kreyenbuhl has contributed extensively to the development of evidence-based treatment guidelines for schizophrenia, serving as a co-investigator on the first update and principal investigator of grants funded by the NIMH and the VA to support the second update of the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. She also served as a consultant to the American Psychiatric Association (APA) during their effort to update the Practice Guideline for the Treatment of Patients with Schizophrenia in 2004. In addition, Dr. Kreyenbuhl has expertise in the area of medication adherence and has received support from NARSAD to evaluate adherence to antipsychotic and oral hypoglycemic medications in individuals with schizophrenia and Type 2 diabetes. She is also interested in methods to improve screening for the metabolic side effects of antipsychotic medications. She has received grant funding from VA HSR&D to determine if providing computerized, personalized health information directly to veterans with serious mental illnesses on whether their care adheres to screening guidelines for side effects increases rates of screening and activates patients to discuss screening with their providers. She is currently pursuing research funding on other computer-technology based interventions for individuals with serious mental illnesses, including the development and testing of a Smartphone application for enhancing adherence to antipsychotic medications. Dr. Kreyenbuhl has authored or co-authored over 50 publications in peer-reviewed journals.
Kreyenbuhl J, Slade EP, Medoff DR, Brown CH, Ehrenreich B, Afful J, Dixon LB. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. In press, Schizophrenia Research.
Kreyenbuhl J, Leith J, Medoff DR, Fang L, Dickerson FB, Brown C, Goldberg RW, Potts W, Dixon LB. A comparison of adherence to hypoglycemic medications between type 2 diabetes patients with and without serious mental illness. In press, Psychiatry Research.
Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M. Does adherence to medications for Type 2 diabetes differ between individuals with versus without schizophrenia? Schizophrenia Bulletin 2010; 36(2): 428-435.
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009. Schizophr Bull 2010 Jan; 36(1):94-103.
Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophr Bull 2010 Jan; 36(1):71-93.
Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J. The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements. Schizophr Bull 2010 Jan; 36(1):48-70.
Kreyenbuhl J, Nossel IR, Dixon LB. Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: A review of the literature. Schizophrenia Bulletin 2009; 35 (4):696-703.
Kreyenbuhl J, Medoff DR, Seliger SL, Dixon LB. Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes. Schizophrenia Research 2008; 101: 256-265.
Kreyenbuhl J, Marcus SC, West JC, Wilk J, Olfson M. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatric Services 2007; 58(7): 983-990.
Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Antipsychotic polypharmacy in the VA Health System: Patient characteristics and treatment patterns. Psychiatric Services 2007; 58(4): 489-495.
Kreyenbuhl J, Dickerson FB, Medoff DR, Brown CH, Goldberg RW, Fang L, Wohlheiter K, Mittal LP, Dixon LB. Extent and management of cardiovascular risk factors in patients with Type 2 diabetes and serious mental illness. Journal of Nervous and Mental Disease 2006; 194 (6): 404-410.
Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research 2006 May; 84(1):90-99.
Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl):1-56.
Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, Sandson N. The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003. Schizophrenia Bulletin 2004; 30(2):193-217.
Lehman AF, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden L, Kreyenbuhl J. Evidence-based treatment for schizophrenia. Psychiatr Clin North Am 2003; 26(4): 939-54.